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Editorial
What sets colorectal cancer (CRC) apart from otherforms of cancer as a serious population health issue?
The succinct but profound answer is that it is the ‘‘most
preventable yet least prevented’’ form of cancer.1
Because CRC usually does not cause symptoms until the
disease is well advanced, timely preventive screening is
generally understood to be vitally important. But despite the
availability of multiple modalities, ranging from at-home
tests to colonoscopy procedures, adherence to CRC screen-
ing guidelines remains alarmingly low in the United States.
For example, one study of a continuously insured population
showed a mere 64% adherence to the US Preventive Ser-
vices Task Force (USPSTF) recommendations over a
10-year period. Of the individuals who were tested, more
than 99% were screened via colonoscopy.2
The National Colorectal Cancer Roundtable (NCCRT) has
set a goal of achieving screening rates of 80% in every com-
munity across the United States.3 Although ambitious, this goal
is realistically attainable given the number of nationally re-
commended screening tests that range from easily obtained
stool samples to more invasive structural examinations.
In 2014, health technology innovator Exact Sciences,
Corp. (Exact Sciences) introduced a noninvasive CRC
screening test using principles of biology, chemistry, and
molecular biology. This powerful combination of technol-
ogies is packaged into a convenient and highly effective
CRC screening test. The multi-target stool DNA (mt-sDNA
or Cologuard) test employs a multi-marker approach to
detect hemoglobin and altered DNA (mutations and meth-
ylations) that is a distinguishing feature of the company’s
technology platform.
We view this new technology as a potential game changer
in closing the CRC screening gap. The accruing evidence
suggests that the mt-sDNA test is a cost-effective alternative
to colonoscopy and other stool-based tests (fecal immu-
nochemical test [FIT], fecal occult blood test [FOBT]) for
a significant portion of the population.4,5 That said, a
compelling case can be made for the test as a beneficial,
population health-based intervention – particularly in a
value-based payment setting. This is good news but, as in
most cases, the devil is in the details.
Although it is difficult to change established practice
patterns, prior generations of clinicians were convinced to
order colonoscopy when endoscopy became widely avail-
able rather than performing digital rectal examinations.
Today’s clinicians routinely order colonoscopy as a first-line
CRC screening test; the next step may be convincing them
to consider the mt-sDNA test as an option for patients at
average risk for CRC because of its demonstrated clinical
value, 3-year test interval, and appeal to patients.
As with most preventive health behaviors, patient adher-
ence to CRC screening recommendations is a challenge. We
believe that employers are a potentially influential sector and a
largely untapped resource in the effort to increase CRC
screening rates. Communication about, and promotion of,
preventive screening by employers goes well beyond im-
proving the health status of employees. It adds value by ef-
fectively reducing the direct and indirect costs of the disease.
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In collaboration with Exact Sciences, the Jefferson Col-
lege of Population Health ( JCPH) organized and convened a
1-day advisory board meeting of health professionals to
discuss the value proposition of mt-sDNA for CRC screening
in terms of clinical quality, risk management, finances, and
population health management.
Overview/Background
Highly prevalent and disturbingly insidious, colorectal
cancer (CRC) imposes a heavy toll on the health of the US
population. It is the second leading cause of cancer mortality
and is expected to cause about 53,200 deaths by the end of
2020.6 With nearly 150,000 new cases diagnosed per year,
health care costs are estimated to approach $14 billion for
the 10-year period ending in 2020.2,6
Overall, the lifetime risk of developing CRC is about
4.49% for men (1 in 22) and 4.15% in women (1 in 24). Risk
factors include personal and family history, physical inac-
tivity and obesity, nutritional status, smoking, and race.
Black Americans have the highest rates of nonhereditary
CRC, and CRC is the leading cause of death in this popu-
lation, particularly among black women7 (Figure 1).
As a result of increased screening and improved treat-
ments, the overall death rate from CRC has decreased
gradually over the last decade.8 However, deaths from CRC
among people younger than age 55 have increased 1% each
year from 2007 through 2016.6 Consequently, the American
Cancer Society recently lowered the recommended age for
beginning preventive screening from 50 to 45.9
According to a 2016 retrospective claims analysis of a con-
tinuously insured population, only 64% of the target population
adhered to USPSTF recommendations for CRC screening.10 In
fact, screening rates remain below the nationwide target of 80%
regardless of state, age, or ethnicity11 (Figure 2).
As in many cancerous conditions, early detection of CRC
is critical to favorable outcomes. If diagnosed at Stage I, 9
out of every 10 patients survive at least 5 years.11 However,
statistics show that only 39% of CRCs are diagnosed at
Stage I or II.11 Prospects of survival diminish substantially
for patients diagnosed at later stages. Statistics reveal that,
of the 61% of patients diagnosed at Stages III or IV, the
5-year survival rate drops to 1 out of every 10 patients.11
Low screening rates can be attributed in part to reported
barriers at the patient, provider, and system levels.12 Patient-
reported barriers include fear of a test, unpleasant prep, lack
of knowledge, physical discomfort associated with a test,
cost or lack of insurance, fear of learning the results, and
inconvenience.12 System-level barriers perceived by pro-
viders include lack of an effective strategy (eg, reminders)
to promote cancer screening and lack of support staff to
utilize such resources.13
Current preventive testing guidelines (eg, American
Cancer Society, USPSTF, National Comprehensive Cancer
Network) and quality measures (eg, Healthcare Effective-
ness Data and Information Set [HEDIS]) specify a variety of
cancer screening options that may be presented to patients
at average risk for CRC. Stool-based tests and recommended
frequencies include FOBT every year, FIT every year, and
mt-sDNA every 3 years.14 Structural examinations and
recommended examination intervals include flexible sig-
moidoscopy every 5 years, computerized tomography colo-
nography every 5 years, and colonoscopy every 10 years. To
date, no specific test is recommended for CRC screening, and
there are no head-to-head studies demonstrating the superi-
ority of one over the others in terms of effectiveness.15
However, the recommendation for CRC screening includes
offering patients the opportunity to select either a structural
(visual) examination or a high-sensitivity stool-based test,
depending on patient preference and test availability.9
Exact Sciences, an innovative health technology com-
pany, designed the mt-sDNA test to improve the accuracy of
noninvasive CRC screening, facilitate provider and patient
adherence to screening guidelines, and reduce the total cost
of CRC care. Leveraging principles of biology, chemistry,
and molecular biology, the mt-sDNA test packages several
technologies in a single, highly effective precancer and
cancer screening test. The test’s combined 11 molecular
biomarkers generate a ‘‘positive’’ or ‘‘negative’’ CRC
screening result. Positive mt-sDNA test results should be
followed up by a diagnostic colonoscopy, and individuals
with negative results who remain at average risk for CRC
should be rescreened for CRC in 3 years.9
A 10,000-patient study showed that the mt-sDNA test is
highly sensitive in comparison with FIT (92% sensitivity vs.
74% with FIT). The specificity of mt-sDNA is 87% versus
95% for FIT; however, measured over a 3-year period (3 an-
nual FIT tests, 1 mt-sDNA test), specificities are similar.15
Understanding the total cost of care associated with
screening tests is an important element in value-based care.
Given the substantial variation in recommended CRC test-
ing modalities, direct cost comparisons are challenging at
best. Even for a particular modality, screening costs may
vary considerably.16,17 For instance, costs associated with
negative screening colonoscopy procedures in the United
States may range from $700–$2000 depending on the type
of sedation, setting, health system, and insurance coverage.
However, it is generally accepted that the total cost of any
CRC screening test (eg, FIT, mt-sDNA) should include di-
rect nonmedical costs, and indirect administrative, pro-
grammatic, and navigation costs.18,19
The direct and indirect cost burden of CRC is substantial
for patients, families/caregivers, employers, and public and












FIG. 1. Colorectal screening rates (%) by ethnic group
(2015). Adapted with permission Source: American Cancer
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commercial payers. First-year treatment costs alone are
staggering; $57,901 for patients diagnosed in Stages I or II
and $108,599 for patients diagnosed in Stage IV.20 With
more than 60% of patients diagnosed in Stages III and IV,
there is a clear opportunity to improve outcomes and lower
costs through screening and early detection.
In addition to being a lower cost alternative to colono-
scopy for a substantial portion of the population, the mt-
sDNA test is supported by an embedded nationwide patient
navigation program that promotes patient adherence, ad-
dresses questions related to completing the test, and manages
inbound calls from health care providers to the central lab-
oratory. The program includes patient outreach and re-
minders during the first month after the test order is received.
Telephonic support is available on a 24/7/365 basis for pa-
tients and health care providers in more than 240 languages.
The company aims to partner with payers and employers
(who purchase health insurance plans for employees) in its
FIG. 2. US colorectal cancer screening test use (%) in adults 50 years and older by state (2018). Reproduced with
permission from the American Cancer Society. Colorectal cancer facts and figures, 2020–2022. https://www.cancer.org/
content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-
figures-2020-2022.pdf Accessed March 25, 2020.
288 NASH ET AL.
effort to increase early detection of CRC. According to the
Kaiser Family Foundation, employer-sponsored health in-
surance plans cover more than 50% of the US non-elderly
population, and national data reveal CRC screening rates
of less than 50% for the population of individuals aged
50–54.21 Although nearly 80% of employers offer wellness
programs, preventive screening for CRC and other diseases
appears to be underutilized. For this reason, the company
seeks to create value and unique offerings that expand ac-
cess to preventive services, maximize workforce health
status and productivity, and reduce overall costs of CRC.
Proceedings
In collaboration with Exact Sciences, JCPH organized
and convened a 1-day advisory meeting of key stakeholders
to discuss the value proposition of using mt-SDNA for CRC
screening in terms of clinical quality, risk management, fi-
nances, and population management. The September 13,
2019 meeting provided an opportunity for the Exact Sci-
ences team to connect with a range of health professionals
with expertise in population-based clinical service, quality
improvement, hospital and integrated delivery system risk
management, and health policy.
POPULATION HEALTH ADVISORY BOARD
MEMBERS
Rajesh Davda, MD, MBA, National Medical Director,
Network Performance Evaluation and Improvement,
Cigna Healthcare, Hartford, CT
Raymond J. Fabius, MD, Principal, AB3 Health LLC,
Philadelphia, PA
Kimberly Hutton, MD, Chief Medical Officer, Care
ATC, Tulsa, OK
Michael D. Lappi, DO, MPH, Chief Health Officer,
Corning Inc., New York, NY
Ginger Miller, OTR/L, CLT, CEAS, Health Promotion
Manager, Utz Quality Foods LLC, Hanover, PA
Ronald E. Myers, DSW, PhD, Professor and Director,
Division of Population Health Science and Center for
Health Decisions, Thomas Jefferson University, Phila-
delphia, PA
Steven Peskin, MD, MBA, FACP, Executive Medical
Director, Population Health and Transformation, Horizon
Blue Cross/Blue Shield of New Jersey, Newark, NJ
Angela Sherwin, MPH, President, Population Health
MSO, Steward Health Care Network, Providence RI
Mark D. Smith, MD, MBA, Clinical Professor of
Medicine, University of California, San Francisco, CA
Moderated by David B. Nash, MD, MBA, (Founding
Dean Emeritus, JCPH), the meeting was structured to fa-
cilitate discussion around the following questions:
1. How can the value of mt-SDNA be demonstrated to
payers, providers, and employers via (1) population
health strategies and initiatives and (2) a value-based
payment paradigm?
2. How can technology be leveraged more effectively to
engage consumers?
3. How can Exact Sciences make a greater impact on
helping all stakeholders meet the NCCRT US goal of
80% screening of eligible persons in every community?
The goal of the meeting was to learn more about ways in
which the company might extend and amplify its work and
support consumers to choose the CRC screening test that is
best for them.
Access, Outcomes and Population Health:
Exact Sciences Perspective
Laura T. Housman, MPH, MBA (Head of Access, Out-
comes, and Population Health, Exact Sciences) presented a
high-level overview of Exact Sciences. By partnering with
health care providers, payers, patients, and advocacy groups
to help eradicate colon cancer, the company envisions
playing a meaningful role in winning the war on cancer
through early detection.
The advantages of the company’s product include:
1) The mt-sDNA test includes 11 molecular biomarkers
(including hemoglobin) that are analyzed to provide a
single ‘‘positive’’ or ‘‘negative’’ result; a ‘‘positive’’
result indicates the need for a follow-up colonoscopy.
2) A state-of-the-art central laboratory that performs
proprietary DNA chemistry.
3) A flexible automated platform.
4) Regulatory approval (parallel review Food and Drug
Administration approval and Centers for Medicare &
Medicaid Services national coverage decision).
5) Commercial scale operations.
Substantial investments the company has made in access,
outcomes, and population health have resulted in greater
involvement of employers as both payers and workplace
health care innovators. Efforts also have spurred the de-
velopment of patient/consumer-initiated physician ordered
testing, retail outlet pathways to reach patients/consumers
(eg, CVS, retail stores), and a rise in population health-
based research and programs and health economics and
outcomes research (eg, addressing patient care gaps, re-
ducing disparities).
The company’s strategic focus is on creating value for
customers across multiple core areas related to cancer di-
agnostics and treatment. For instance, via a contract with the
state of California, mt-sDNA is offered to Medicaid fee-for-
service enrollees across the system. Currently, more than
94% of patients using mt-sDNA report having no out-of-
pocket costs.
Advisor insights were requested regarding (a) how pro-
grammatic population health approaches improve access to
wellness and prevention offerings, and (b) how to improve
engagement and adoption of mt-sDNA as a first-line
screening choice for individuals at average risk for CRC.
Key discussion points
 Experts advised focusing on outcomes reported by
recognized benchmark employers to determine whether
wellness programs are having the desired effect in
terms of improving preventive screening rates.
 With respect to the impact of incentives on engage-
ment, experts advised pursuing large health systems
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with a systems strategy in which economic incentives
are aligned with clinical incentives. Collaborative work
relationships make things happen.
 Regarding the impact of cost sharing on uptake of
preventive services, experts advised working with state
health programs (eg, New Jersey’s preventive services
program).
Population Health Strategies and Opportunities
for CRC Screening
Emphasizing the prevalence of CRC, the associated public
health and economic burdens, and the significant preventive
screening gap in the United States, Philip D. Parks MD,
MPH (Senior Director, Population Health, Exact Sciences)
shared the company’s perspective on opportunities for CRC
screening and associated population health strategies. Of
particular concern, the burden of CRC within the group aged
45–49 years now exceeds that in the group aged 70–74
(Figure 3). In 2018, the American Cancer Society revised its
CRC screening guidelines for individuals at average risk for
CRC to include patients 45 years and older.
Low screening rates across different demographic and
population segments can be attributed to reported patient-
and system-level barriers. The evidence shows that early
detection of CRC can lead to increased survival and de-
creased treatment costs. The company takes a risk-based
approach to CRC screening via supporting shared decision
making through clinical pathways and protocols (Figure 4).
Dr. Parks reviewed evolving health care trends, noting the
importance of aligning technologies and solutions with
health care stakeholders, public health needs, and patient
preferences and values. He posed several questions:
 How do we calculate and report total costs of CRC
screening? For example, administrative, programmatic,
and other nonclinical costs are factors in the total cost
of a FIT test.
 Should return on investment models be designed to
help employers understand the costs and consequences
of increasing CRC screening rates among their em-
ployees? If so, what inputs and outputs are needed for
financial models?
Key discussion points
 Advisors concurred that the increasing incidence of
CRC in the group aged 45–49 is an important signal for
population health advocates and for the nation’s em-
ployers as they consider whether to cover the cost of
CRC screening for their employees. National experts
now recommend that the relevant HEDIS quality
measure be expanded to include ages 45–49. This also
ties in with a value-based approach.
 A measure of upstream mortality prevention through
screening and early detection is very important but not
well known among employers and other stakeholders.
We know that the costs associated with CRC are
enormous, but they are not well understood or easily
quantified. Chief financial officers are concerned about
the total cost of care for employees; a convincing case
can be made that the total cost of care will decrease as
we do a better job of screening.
 Regarding barriers to screening, advisors suggested
systematizing screening, offering choices for screening
when appropriate, leveraging technology, and encour-
aging provider offices to allow staff to work at the top
of their licensure.
 Patients perceive trusted clinicians as ‘‘honest brokers.’’
The evidence shows that completion of preventive
screening tests is demonstrably greater when the patient
has a positive relationship with the ordering physician.25
 The best test is the one that will get done. CRC
screening will not be driven solely by consumer de-
mand; the consumer must be prompted to act by the
physician. Providers can be incentivized via Medicare
Advantage Stars credit and payment.
Implementation of CRC Screening Programs:
State of the Art and Science
Advisory Board member Ron Myers, DSW, PhD shared
information on 3 ‘‘outreach’’ randomized controlled trials
(RCTs) in CRC screening. The studies evaluated the impact
of evidence-based standard interventions with and without
tailored navigation in CRC screening for (1) a general
population, (2) an African American population, and (3) a
Hispanic American population. Researchers concluded that:
(1) giving primary care patients a choice matters; (2) a
centralized decision support and navigation outreach strat-
egy can increase health system CRC screening and reduce
disparities; and (3) infrastructure and protocols are needed
to support implementation of an intervention in diverse
populations.
Dr. Myers emphasized the importance of a collaborative























FIG. 3. Distribution of colorectal cancer screening burden
by age at diagnosis (2010–2014): person-years of life lost
because of colorectal cancer by age at diagnosis among
patients followed for 20 years after diagnosis. EHR, elec-
tronic health record. Adapted with permission from John
Wiley and Sons. Wolf AMD, Fontham ETH, Church TR,
Flowers CR, Guerra CE, LaMonte SJ. Colorectal cancer
screening for average-risk adults: 2018 guideline update
from the American Cancer Society. Figure 4B. CA Cancer J
Clin 2018;68:250–281.
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concept. Health systems should employ cadres of navigators
and provide training programs. State of the art navigation and
decision support research is focused on empowering patients
without adding to the primary care provider’s burden.
Key discussion point
Problems arise when a choice must be made among too
many options; whenever possible, offer patients a choice
between 2 options. Always give consumers the opportunity
to choose the least invasive test.
One Payer’s Perspective: Cigna National Colon
Cancer Screening Program
Advisory Board member Rajesh Davda, MD, MBA,
presented an overview of Cigna’s National Colon Cancer
Screening Program. The main program features include 3
outreach modalities (ie, direct mail of FIT collection kit,
brochure, web-based promotion), customization/collabora-
tion (eg, coaches, case managers, Cigna Collaborative Care
practices craft message from physician), and impact mea-
surement via HEDIS data collection and reporting. Studies
show that direct mailing and outreach resulted in statisti-
cally significant results compared with the control group.
An estimate of avoided medical costs for patients who
tested positive and followed through with diagnosis and
treatment is 4 times the cost associated with initial screening
and colonoscopy.
An American Cancer Society/Cigna survey concluded
that patients who completed a test kit were more likely to
complete a test kit in the future.
Preventing Colon Cancer Deaths and Disabilities:
Value to the Provider, Payer, and Employer
Advisory Board member Raymond Fabius, MD, dis-
cussed the value of preventing CRC deaths and disabilities
from the perspectives of 6 specific constituencies with dif-
ferent needs and expectations: (1) patients/health care con-
sumers, (2) clinicians, (3) payers (insurance companies,
health plans, third-party administrators), (4) purchasers
(employers, government), (5) consultants (brokers), and (6)
suppliers (pharmaceutical, laboratory, and disposable med-
ical equipment).
When one of these constituencies has an issue, opportu-
nity lies in helping to match that constituency with the best-
suited service. For example: for providers, make things
easier by helping to track quality scores such as CRC
screening rates in their practices; for purchasers, help im-
prove employee engagement with evidence-based guide-
lines to maximize productivity while demonstrating that the
company cares about employee health and well-being.
Suppliers are an excellent source of knowledge and in-
sights as well as potential distribution channels. For exam-
ple, consider that >80% of people in the United States live
within 8 miles of a supplier such as CVS or Walgreens.
Building a national culture of health starts with preven-
tion strategies: primordial prevention (eg, clean water),
primary prevention (eg, immunizations), secondary pre-
vention (eg, screenings), tertiary prevention (eg, compliance
with care management guidelines). We should strive to
make it culturally unacceptable for a person or population
not to be screened for CRC.
Where do we start?
 At the national level, CRC screening rates are subop-
timal even for the best-performing states. Find ways to
move the needle.
 At the health plan level, look at those who are doing the
best job, find out why, and determine how to get others
to improve.
 At the employer level, analyze cost data (eg, screening,
high-cost claimants, long-term disability). There is a
direct correlation between the health status of em-
ployees and the ‘‘culture of health’’ at an employer site.
Conduct a pilot project at the best-performing employer
ELIGIBLE PATIENT IDENTIFICATION OUTREACH
FOLLOW UP SCREENING DIALOGUE
Leverage EHR system to identify 
eligible patients for screening19
Reach out to eligible patients informing 
them they are due for screening9
Present & discuss screening options to patients to 
choose a preferred screening modality, considering 
age, efficacy, adherence, cost & risk9,21
Initiate discussions between providers 
and patients regarding the importance 
of colorectal cancer screening20
Ensure follow through on screening and  continued 
screening at appropriate intervals through 
structured responses at prescribed times19
FIG. 4. CRC screening process.9,22–24 CRC, colorectal cancer.
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site to establish a new benchmark in CRC screening
and to show what is possible to achieve.
 At the patient level, create personalized incentives (eg,
lower or zero co-pay for completing the screening
process, financial rewards).
Suggested solutions Include: collaborative screenings (eg,
universal cancer screening that meets employer, health plan,
provider, and patient needs); education, marketing, and
motivation; and creating competition around rewards and
recognition (eg, best employer, best delivery system).
Roundtable Discussion 1
Discussion questions were posted on the walls of the
conference room and Advisors were asked to offer brief
responses via Post-It Notes. A roundtable discussion ex-
panded on these responses.
How can Exact Sciences make a greater impact
in helping health care stakeholders meet the NCCRT
goal of 80% of eligible persons screened for CRC
in every community?
Advisors agreed that patient check-in is the single most
important element to ensure that information related to
screening status is captured. Processes adopted by risk-
bearing groups (accountable care organizations [ACOs],
Medicare, capitated health plans) include filling out forms
(including screening) when the patient arrives for an office
visit, and figuring out how to incorporate this in the current
workflow between the health care provider’s office and the
patient.
Advisors also concurred that there is a ‘‘disconnect’’
between the provider dialogue with the patient and the
screening. They proposed pre-staging mt-sDNA in physi-
cian offices. To allow the patient a choice, FIT and mt-
sDNA tests could be stocked and given directly to patients.
Stocked kits must include bar codes that can be associated
with specific patients. A designated staff member could be
trained to do motivational interviewing.
Other recommendations included:
 Develop/implement a patient assistance program.
 Engage employer support networks. Noting that the
average patient must take time off from work for co-
lonoscopy may resonate with employers.
 Explore partnering opportunities with the Veterans
Administration and Department of Defense.
 Work on developing studies to establish benchmarks.
 Explore ways in which the test might become the de-
fault test in the ‘‘Tele-doc’’ and health promotion space
for consumers who do not visit doctors.
How can value be demonstrated to payers, providers,
and employers through population health strategies
and initiatives?
Advisors encouraged the company to help establish a US
benchmark for CRC screening. ‘‘Keeping well people well’’
requires a population health strategy that includes commu-
nicating with people and sharing anecdotes about how to
avoid CRC.
Demonstrate value to providers and payers by emphasizing
the test’s contribution to a potential reduction in over-
screening and overdiagnosis as well as under-screening and
missed early diagnosis. In Medicare Advantage insurance
markets, there is already potential for providing financial
incentives to providers who improve and maintain Star rat-
ings that are aligned with quality measures (including CRC
screening rates). For employers, provide tool kits (videos,
flyers) that are customized for their employee population(s).
From a quality perspective, systematic follow-up of
positive tests is imperative. A positive mt-sDNA test is
comparable to a suspicious mammogram, and all positive
stool-based test results (including FIT, FOBT and mt-
sDNA) should be followed by colonoscopy. Recruit teams
and establish processes and protocols to ensure appropriate
outreach and navigation for individuals with positive stool-
based test results.
How can value be demonstrated to payers, providers,
and employers in a value-based payment paradigm?
Purchaser/Employer perspective: The corporate physi-
cian executive – as an ‘‘honest broker’’ – may be the driver
for a mass audience. Explore the potential purchasing power
of employer coalitions or onsite medical vendors to nego-
tiate direct contract pricing for mt-sDNA.
Explain the value of early detection in terms of decreased
overall cost, improved productivity, decreased short- and
long-term disability, and quality-adjusted life years.
Provider perspective: For the provider, value lies in
mastery, autonomy, rewards, and recognitions. Understand
the mission of ACOs and equity-backed primary care pro-
viders and explore potential relationships.
Health plan perspective: Value lies in customer loyalty,
member satisfaction, health outcomes, market share, and
decreased total costs.
Consider whether patients on a 10-year negative colo-
noscopy screening regimen might elect to have mt-sDNA
for their next screen rather than repeat colonoscopy.
How can technology be leveraged to engage
consumers on their health journey?
 Consider what happens in the case of a positive result
for Medicaid beneficiaries and those who are unin-
sured. Is there financial assistance for these patients?
 Leverage technology to simultaneously reach/educate
patients and incentivize providers (eg, in physician of-
fices, a patient information intake system [eg, Phreesia]
can replace the patient clipboard with a wireless touch
screen and swipe card enabled PhreesiaPad).
 Understand employer data and methods of communi-
cation for engaging, educating, and empowering em-
ployees.
 Develop a personalized multimedia campaign to drive
screening adherence using text messaging, social me-
dia, testimonials, and behavioral economics.
For guidelines to change, the case must be made at the
societal level. If the data support societal change, advisors
suggested that the company undertake a 10-year campaign
with the goal of mt-sDNA becoming ‘‘the’’ first-line choice.
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Roundtable Discussion 2
Comparisons Among Available CRC Screening Tests
Comparative test performance and accuracy: Accuracy is
comprised of sensitivity and specificity. The clinical goal of
a screening test is to balance potential risk and harm with
high sensitivity and specificity. In the case of a CRC
screening test, a highly sensitive test results in the lowest
number of missed cancers; a highly specific test results in
lowest number of nonproductive colonoscopies. The sensi-
tivity of FIT is 74% versus mt-sDNA at 92%; the specificity
is 95% and 87%, respectively. Over a 3-year period of an-
nual FIT tests vs. 1 mt-sDNA test, the specificities are
similar.26 The diagnostic accuracy of colonoscopy is de-
pendent on factors such as the right prep, the right skill set,
and the right facility. If mt-sDNA is a more accurate test
than FIT, the company should generate evidence and com-
pete for preferred screening test status among payers, em-
ployers, and other purchasers.
Accountability: Today, accountability for any screening
test rests with the primary care provider. However, some of
the specialist’s ‘‘bread and butter’’ volume comes from
doing things that are more appropriately done by primary
care providers (eg, managing prostatitis). The world is
moving toward capitated screening, and the process is best
managed by primary care physicians.
Culture change: Colonoscopy is considered ‘‘gospel’’ and
the ‘‘gold standard’’ in primary care today, and health plans
will be followers rather than leaders with respect to clinical
practice recommendations. Managed care plans might con-
sider partnering with the company; however, there is low
probability of early adoption without real-world clinical ev-
idence of the value of mt-sDNA in an appropriate population.
Mt-sDNA is a screening test for detecting adenoma and
CRC whereas colonoscopy is a procedure to detect ade-
noma. Perhaps the primary care physician should be held
accountable only for screening tests; accountability for di-
agnostic colonoscopy would rest with the gastrointestinal
specialist.
Delivery systems can contribute but will not lead cultural
change. Early adoption happens within benchmark organi-
zations where employees are encouraged to take care of
themselves and their coworkers. Cultural transformation
makes it socially unacceptable to not have preventive
screening. Lifestyles have overwhelming influence on can-
cer rates. Promotion of behaviors such as weight manage-
ment, healthy eating, nonsmoking, and regular exercise
must be encouraged.
Budget impact/cost effect: If a screening test is part of a
bundle, it has potential to move to the front line. The best
result will occur when payers and providers are aligned.
Most employers will not purchase individual point solutions
and will rely on health plans to administer benefits and
health care resources.
Interventions: The behavior modification industry has a
wide variety of software and patient connectivity tools and
payers have data. Avoid reporting fatigue (ie, multiple
doctors asking about the last colonoscopy) by centralizing
the population-level data for CRC screening. Use technol-
ogy to identify eligible patients. Target patients with in-
centives based on individual needs (eg, gift cards and/or free
meals based on spending patterns and needs).
Develop pilots to test interventions (eg, incentives, pro-
vider offices).
What has worked?
Engaging consumers – JCPH helped build the CVS
Minute Clinic model and Philadelphia is home to the Con-
venient Care Association. Patients could pick up test kits at
Minute Clinics. The complete process can be done at Wal-
greens. Primary care practitioners are on-site at CVS/Aetna,
Walgreens/Humana.
Personalization – Studies show that it is important to
determine how to deliver reminders and send material with
photos of and references to someone who is similar to the
intended recipient.
Roundtable Discussion 3
Dr. Nash asked Advisors for their 2 most important
takeaway messages; their responses are summarized below:
General observations and recommendations
Clinicians agreed that a screening test should be readily
accessible (ie, inexpensive, physician prescription unnec-
essary, ‘‘order on Amazon’’). By that definition, colono-
scopy is not a screening test. Mt-sDNA is a tool that can
help bring preventive screening back into the primary care
setting; the test might even be done during an office visit.
Advisors also suggested that incorporating the very
‘‘human’’ aspects of CRC (eg, impact on patients, care-
givers) can be helpful in personalizing communications.
Stories related to early detection and survival can put a real
‘‘face’’ on CRC.
Re: employers
Help employers understand the total costs of CRC for
their unique workforces by developing information on the
incidence of CRC and its associated costs in the context of
overall health care (including oncology) spending and in-
direct costs (eg, disability, labor replacement). Design a
study to answer population-based questions. For example,
integrated delivery systems can use CRC screening data and
absentee data from their employee populations to calculate
cost savings over a 10-year period.
In general, an employer’s workforce can be sorted into
4 distinct groups in terms of health care seeking behavior:
(1) 20% who research and access care independently (eg,
engineers), (2) 30% who prefer shared decision making with
a trusted clinician, (3) 30% who want their doctors to make
all decisions for them, and (4) 20% who are completely
divorced from the health care system (eg, young men). Each
cohort requires a different approach.
Other valuable advice included:
 Learn to speak the language of employers and engage
in conversations with employer coalitions.
 Engage with data analytics groups to show value to
employers across the board.
Re: providers
Consider what it would take to screen 100% of the pop-
ulation according to clinical guidelines and take action. For
instance:
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 Design a ‘‘one-click solution’’ and help train staff to
work with patients in a standardized way.
 Promote benchmarks in each constituency as well as
global benchmarks, and do not underestimate the power
of ‘‘shaming’’; providers are very competitive.
Explore relationships with ACOs and equity-backed pri-
mary care practices.
Re: research
Plan and execute demonstration projects, including: (1)
deciding what to put in place with an employer/purchaser or
health system, (2) bringing stakeholders into alignment on
goals and objectives, and (3) implementing evidence-based
interventions to drive the initiative and create real-world
examples of improving screening rates.
Address disparities. In addition to rural populations,
consider the 25%-40% of commercially insured consumers
who have no medical home21 and develop a plan for
screening the medically homeless.
Re: payers
Collaborate on bundling arrangements for large GI
practices to manage the screening and diagnostic compo-
nents of testing. Screen with the most appropriate test
(in terms of combined efficiency, cost, patient-centeredness,
staged diagnosis) and determine the associated metrics.
Conclusion
JCPH, in collaboration with Exact Sciences, organized
and convened an advisory meeting of health professionals to
discuss the value proposition of the mt-sDNA test for CRC
screening in terms of clinical quality, risk management, fi-
nances, and population management. Expert opinions were
aligned regarding the profound negative implications and
substantial clinical, financial, individual, and population
health costs associated with a failure to meet the NCCRT
goal of 80% CRC screening rate in every US community.
Likewise, there was concurrence among experts that CRC
screening options for individuals at average risk for CRC
must be effective, accessible, easy to use, and offered as part
of a shared (clinician/patient) decision-making process that
takes into account disparities among cultural and ethnic
groups in urban and rural settings. The thoughtful discus-
sions among Advisors revealed multiple opportunities for
immediate implementation as well as recommendations for
further review and exploration.
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